

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Cancer Treatment Reviews

journal homepage: www.elsevier.com/locate/ctrv

Corrigendum

Corrigendum to “Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis” [Cancer Treat. Rev. 125 (2024) 102704]

K.R.J. Kistemaker^{a,b,c,*}, F. Sijani^a, D.J. Brinkman^{b,d}, A. de Graeff^e, G.L. Burchell^f,
M.A.H. Steegers^{b,c,1}, L. van Zuylen^{a,c,1}

^a Amsterdam UMC Location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, Amsterdam, The Netherlands

^b Amsterdam UMC Location Vrije Universiteit Amsterdam, Anesthesiology, De Boelelaan 1117, Amsterdam, The Netherlands

^c Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands

^d Amsterdam UMC Location Vrije Universiteit Amsterdam, Internal Medicine, Section Pharmacotherapy, De Boelelaan 1117, Amsterdam, The Netherlands

^e Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Academic Hospice Demeter, de Bilt, The Netherlands

^f Medical Library, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

The authors regret that in the abstract of the article an incorrect mean difference in Bowel Function Index between oxycodone/naloxone and oxycodone with laxatives is described in the results. In the abstract a mean difference of -13.68 (95 % CI -18.38 to -8.98 ; $I^2 = 58$ %) is described, where it should be -13.79 (95 % CI -18.50 to -9.08 ; $I^2 = 34$ %). In the rest of the article the mean difference is mentioned

correctly, as can be seen in figure 2 and in the results section on page 4 (last paragraph). Since it is a very small difference (0.11 points on a scale of 0 to 100), it does not change the interpretation of the results. Also the interpretation of the heterogeneity, represented by the I^2 statistic, is not different, since values of 30–60 % suggest moderate heterogeneity.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ctrv.2024.102704>.

* Corresponding author at: Amsterdam UMC Location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, Amsterdam, The Netherlands.

E-mail address: k.kistemaker@amsterdamumc.nl (K.R.J. Kistemaker).

¹ These authors contributed equally.

<https://doi.org/10.1016/j.ctrv.2024.102738>

Available online 27 April 2024

0305-7372/© 2024 The Author(s). Published by Elsevier Ltd. All rights reserved.

